Search

Displaying results 231 - 240 of 279 in total
  1. Drug

    Tibolone

    go.drugbank.com/drugs/DB09070
    ApprovedInvestigational

    It has been used in Europe for almost 2 decades, primarily for the prevention of postmenopausal osteoporosis and the treatment of post-menopausal symptoms [L1720].

  2. Drug

    Pentoxifylline

    go.drugbank.com/drugs/DB00806
    ApprovedInvestigational

    [A226608] Pentoxifylline has been marketed in Europe since 1972; PTX extended-release tablets sold under the trade name TRENTAL by US Pharm Holdings were first approved by the FDA on Aug 30, 1984, but

  3. Drug

    Allylestrenol

    go.drugbank.com/drugs/DB01431
    Investigational

    It is widely marketed throughout Europe, including Russia and many other European countries, and is also available in Japan, Hong Kong, India, Bangladesh, Indonesia, and much of Southeast Asia, though

  4. Drug

    Droxidopa

    go.drugbank.com/drugs/DB06262
    ApprovedInvestigational

    L-DOPS has been used in Japan and Southeast Asia already for some time, it is also currently in clinical trials at the phase III point in the United States (U.S.), Canada, Australia, and throughout Europe

  5. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued.

  6. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, b...

  7. Drug

    Tirzepatide

    go.drugbank.com/drugs/DB15171
    ApprovedInvestigational

    Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor … [L48766] On September 15, 2022, tirzepatide was also approved by the European Commission.[L44386]. On November 02, 2023, tirzepatide was also approved by the Health Canada [L52800]

  8. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization du...

  9. Drug

    RUS 3108

    go.drugbank.com/drugs/DB05911
    Experimental

    The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.

  10. Drug

    Masitinib

    go.drugbank.com/drugs/DB11526
    InvestigationalVet approved

    It has been available in Europe since 2009, under the brand name Masivet. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.